Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | ATM | Q13315 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | ANPEP | P15144 | 1/20 | 0.43 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 4/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23163258 | 1.00 | MEN1 (0.64) | MEN1KMT2AMAPTATMHSD17B10 | |
| SCHEMBL16115683 | 1.00 | MEN1 (0.64) | MEN1KMT2AMAPTATMHSD17B10 | |
| SCHEMBL862327 | 1.00 | MEN1 (0.64) | MEN1KMT2AMAPTATMHSD17B10 | |
| SCHEMBL14511330 | 1.00 | MEN1 (0.64) | MEN1KMT2AMAPTATMHSD17B10 | |
| SCHEMBL915393 | 1.00 | MEN1 (0.64) | MEN1KMT2AMAPTATMHSD17B10 | |
| SCHEMBL29025599 | 0.97 | KMT2A (0.59) | MEN1KMT2AMAPTATMHSD17B10 | |
| SCHEMBL65035 | 0.97 | — | — | |
| SCHEMBL19617353 | 0.97 | — | — | |
| SCHEMBL25299343 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL8578344 | 0.95 | KMT2A (0.56) | MEN1KMT2AMAPTATMHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111989321-B | KRAS G12C inhibitors | 米拉蒂治疗股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-20240101553-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-03-28 | — | — | US | disclosed |
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| EP-3844151-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-08-23 | — | — | EP | disclosed |
| CN-109843856-B | KRAS G12C inhibitors | 米拉蒂治疗股份有限公司 | 2023-05-02 | — | — | CN | disclosed |
| EP-3710439-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-02-15 | — | — | EP | disclosed |
| US-11267812-B2 | KRAS G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2022-03-08 | — | — | US | disclosed |
| WO-2021063346-A1 | KRAS G12C INHIBITOR AND APPLICATION THEREOF | 上海迪诺医药科技有限公司 | 2021-04-08 | — | — | WO | disclosed |
| EP-3458445-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2021-02-17 | — | — | EP | disclosed |
| CN-111989321-A | KRAS G12C inhibitors | 米拉蒂治疗股份有限公司 | 2020-11-24 | — | — | CN | disclosed |
| EP-3710439-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2020-09-23 | — | — | EP | disclosed |
| US-20200262837-A1 | KRAS G12C INHIBITORS | ARRAY BIOPHARMA INC. | 2020-08-20 | — | — | US | disclosed |
| US-10689377-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2020-06-23 | — | — | US | disclosed |
| US-10633381-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2020-04-28 | — | — | US | disclosed |
| CN-109843856-A | KRAS G12C inhibitor | 米拉蒂治疗股份有限公司 | 2019-06-04 | — | — | CN | disclosed |
| US-20190144444-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2019-05-16 | — | — | US | disclosed |
| US-10125134-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2018-11-13 | — | — | US | disclosed |
| US-20180072723-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144444-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | MEN1 348/4885KMT2A 2081/4885MAPT 3928/4885 |
| US-10633381-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | MEN1 348/4885KMT2A 2081/4885MAPT 3928/4885 |
| US-20200262837-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | MEN1 348/4885KMT2A 2081/4885MAPT 3928/4885 |
| US-11267812-B2 | KRAS G12C inhibitors | KRAS, NRAS, HRAS | MEN1 348/4885KMT2A 2081/4885MAPT 3928/4885 |
| US-10125134-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | MEN1 348/4885KMT2A 2081/4885MAPT 3928/4885 |
| US-10689377-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | MEN1 348/4885KMT2A 2081/4885MAPT 3928/4885 |
| US-20240101553-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | MEN1 348/4885KMT2A 2081/4885MAPT 3928/4885 |
| US-20180072723-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | MEN1 348/4885KMT2A 2081/4885MAPT 3928/4885 |
| US-20230373999-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | MEN1 348/4885KMT2A 2081/4885MAPT 3928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.